Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
Key PointsSamira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000...
Nasdaq News: Markets
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
Key Points15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share...
Nasdaq News: Markets
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Societys...
Business Wire
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +63.04% and +32.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates
Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +54.76% and +22.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -510.13% and -94.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of -48.03% and +1.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Septerna (NASDAQ:SEPN) Now Covered by Stifel Nicolaus
Stifel Nicolaus initiated coverage on Septerna in a research note on Friday. They set a "buy" rating and a $43.00 price objective on the stock...
MarketBeat

Advertisement|Remove ads.